Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

MiR-449a: A Potential Biomarker for Vocal Function Preservation in Combination Therapy for Laryngeal Cancer

Amal F. Gharib
,
Abdulraheem Almalki
,
Amani A. Alrehaili
ORCID logo ,
Afaf Awwadh Alharthi
ORCID logo ,
Ohud Alsalmi
,
Rasha L. Etewa
,
Mutaib M. Mashraqi
ORCID logo ,
Shaimaa A Alharthi
ORCID logo ,
Wael H Elsawy
* ORCID logo
Version 1 : Received: 14 April 2024 / Approved: 15 April 2024 / Online: 15 April 2024 (14:07:49 CEST)

How to cite: Gharib, A. F.; Almalki, A.; Alrehaili, A. A.; Alharthi, A. A.; Alsalmi, O.; Etewa, R. L.; Mashraqi, M. M.; Alharthi, S. A.; Elsawy, W. H. MiR-449a: A Potential Biomarker for Vocal Function Preservation in Combination Therapy for Laryngeal Cancer. Preprints 2024, 2024040982. https://doi.org/10.20944/preprints202404.0982.v1 Gharib, A. F.; Almalki, A.; Alrehaili, A. A.; Alharthi, A. A.; Alsalmi, O.; Etewa, R. L.; Mashraqi, M. M.; Alharthi, S. A.; Elsawy, W. H. MiR-449a: A Potential Biomarker for Vocal Function Preservation in Combination Therapy for Laryngeal Cancer. Preprints 2024, 2024040982. https://doi.org/10.20944/preprints202404.0982.v1

Abstract

Background/Objectives: Laryngeal squamous cell carcinoma (LSCC) is the most prevalent form, accounting for nearly 95% of laryngeal cancer. This study evaluates the effectiveness of chemotherapy and radiation therapy combined for treating LSCC, along with exploring miR-449a as a potential biomarker for predicting treatment response and prognosis in LSCC patients. Patients and Methods: The study had 81 patients with advanced laryngeal cancer and 50 healthy controls. Chemotherapy was given for two cycles, followed by an evaluation of the response. Disease progression cases had surgical resection and radiation therapy. Positive responders had radiation therapy after a third cycle. The study also assessed miR-449a expression levels in tumor tissue, normal tissue, and serum samples from control subjects. Results: 31% achieved a complete response, and 49% showed a partial response. 31% of complete response participants maintained laryngeal integrity and vocal function. After radiation therapy, 74% of 65 patients responded completely and preserved laryngeal functions. Lower MiR-449a levels found in LSCC tissues and serum samples were correlated with aggressive tumor behavior, poor prognostic markers, and decreased survival. Conversely, elevated levels were seen in treatment responders. Conclusions: Combined chemo and radiotherapy preserve vocal function and improve outcomes in LSCC. MiR-449a is a promising indicator for diagnosis and treatment efficacy in LSCC.

Keywords

laryngeal squamous cell carcinoma (lscc); chemotherapy; radiation therapy; mir-449a; biomarker

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.